REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Clinical trials for REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Punch trial aims to tame aggressive blood cancer
Disease control Recruiting nowThis study is testing whether combining two targeted cancer drugs is safe and effective for patients with an aggressive type of lymphoma that has come back or stopped responding to other treatments. The two drugs work together: one delivers a toxin directly to cancer cells, while…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New bridge therapy aims to get more patients to lifesaving CAR-T treatment
Disease control Recruiting nowThis study is testing a drug called odronextamab to see if it can help control aggressive lymphoma long enough for patients to receive CAR-T cell therapy, a potentially curative treatment. The drug is given before the process to collect immune cells for CAR-T begins, with the goa…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New combo therapy aims to rally immune system against tough lymphomas
Disease control Recruiting nowThis study is testing a combination of two drugs, epcoritamab and ibrutinib, for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or stopped responding to previous treatments. The goal is to find a safe and effective dose. One drug helps the body's own immune…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New bridge to a cancer cure: drug combo aims to get more patients to Life-Saving CAR-T
Disease control Recruiting nowThis study is testing a two-drug combination (golcadomide and rituximab) as a 'bridging therapy' for adults with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to control the cancer and improve patients' health so they can qualify fo…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New Two-Pronged attack tested for Tough-to-Treat lymphoma that returns
Disease control Recruiting nowThis study is testing a new treatment sequence for adults whose aggressive large B-cell lymphoma has come back or didn't respond to initial therapy. Participants first receive two targeted drugs (tafasitamab and lenalidomide), followed by a stronger chemotherapy regimen. The main…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New CAR-T therapy trial targets Tough-to-Treat HIV-Related cancers
Disease control Recruiting nowThis early-stage study is testing a personalized immune therapy called axicabtagene ciloleucel (a type of CAR-T) for people with HIV who have an aggressive form of B-cell lymphoma that has returned or not responded to prior treatments. The main goals are to check if the treatment…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
New combo therapy aims to boost Cancer-Killing power of CAR-T
Disease control Recruiting nowThis early-phase study is testing the safety and effectiveness of a new drug called ST-067 when given alongside a personalized immune cell therapy (CAR-T) for patients with aggressive large B-cell lymphoma that has come back or not responded to other treatments. The goal is to se…
Matched conditions: REFRACTORY GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC